RxDoctor Payments Data

Neena Bhatti, MD

Allergy/ Immunology · Waldorf, MDNPI 1114923505

Payments from drug & device makers

$91,050in general payments, 2019–2025

Across 974 payments — averaging $93.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$62K
  • Teva Pharmaceuticals USA, Inc.$7K
  • GSK$5K
  • Regeneron$2K
  • Sanofi$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • plus $10K from 32 others

What the payments were for

  • Consulting fees$2,6249%
  • Speaking & faculty fees$6,72022%
  • Food & beverage$20,81168%
  • Education$4702%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy/ immunology providers in Marylandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$88,239
Medicare patients
135
Services billed
3,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab21$77,354
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$24,257
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$19,478
SymbicortBudesonide/Formoterol Fumarate22$6,893
Breo ElliptaFluticasone/Vilanterol14$6,284
DuleraMometasone/Formoterol13$3,970
Azelastine-FluticasoneAzelastine/Fluticasone25$2,597
Albuterol Sulfate HfaAlbuterol Sulfate93$2,454
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$1,518
Montelukast Sodium69$1,471
Fluticasone Propionate45$1,222
Azelastine Hcl47$1,190
Clobetasol Propionate14$1,174
Levocetirizine Dihydrochloride49$1,048
Hydroxyzine Hcl28$467

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$5,474$30,54148 claims
AstraZenecaBreztri Aerosphere, Symbicort$61,552$26,37050 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy/ immunology providers in Marylandon file to place this against a meaningful peer group, so we don't.

Other allergy/ immunology in Waldorf

Where these figures come from

Is this you, or does something look wrong? →